Trial Profile
A single dose,pharmacokinetic study to compare the oral bioavailability and food effects of two formulations of MK-3682/GZR/MK- 8408 in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Apr 2017
Price :
$35
*
At a glance
- Drugs Grazoprevir/ruzasvir/uprifosbuvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- 08 Apr 2017 New trial record
- 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics